Skip to main content
. Author manuscript; available in PMC: 2019 Dec 3.
Published in final edited form as: Gut. 2016 Jan 4;66(4):724–735. doi: 10.1136/gutjnl-2015-310033

Figure 6. IFN-induced TRAIL expression in NK cells is greater during QUAD therapy than during PegIFN/RBV therapy.

Figure 6.

(A, B) Comparison of changes in the expression level (A) and frequency (B) of TRAIL+ NK cells during the first 24 h of therapy in patients who were non-responders to a full course of PegIFN/RBV therapy but had an SVR during a subsequent course of QUAD therapy.

(A, B) Comparison of changes in the expression level (A) and frequency (B) of TRAIL+ CD56dim NK cells during the first 24 h of therapy in patients who were non-responders to a full course of PegIFN/RBV therapy but had an SVR during a subsequent course of QUAD therapy. Statistical analysis: non-parametric paired Wilcoxon-signed-rank test. Median and IQR are shown in the left graphs in panels A-D.